Altimmune CCO Linda Richardson Receives RSUs; Surrenders Tax Shares

What Happened Linda M. Richardson, Chief Commercial Officer of Altimmune, had 24,000 restricted stock units (RSUs vest) convert into common shares on 2026-09-16 (reported 2026-09-17). The filing shows 24,000 shares acquired at $0.00 (conversion of RSUs), and 6,826 shares disposed to satisfy tax withholding at $3.24 per share, totaling $22,116. After withholding, Richardson retained a net of 17,174 newly issued shares from this vesting event. The conversion is an award/vesting event rather than an open-market purchase or a sale.

Key Details

• Transaction date: 2026-09-16; filing date: 2026-09-17 (timely).
• Converted/Acquired: 24,000 shares via RSU vesting (reported as derivative conversion, code M) at $0.00 exercise price.
• Tax withholding: 6,826 shares disposed (code F) at $3.24 per share for $22,116.
• Implied gross value of vested shares at $3.24/share: 24,000 × $3.24 = $77,760.
• Shares owned after transaction: not disclosed in this filing.
• Footnotes: RSUs represent contingent rights to one share when vested (F1); shares were surrendered solely to cover taxes (F2); RSUs vest 25% on Sept 16, 2026 with remaining vesting over three years (F3).

Context This was a routine vesting of RSUs with shares surrendered to the company to cover tax withholding (a common administrative step), not a market sale or purchase. The filing shows a conversion of derivatives (RSUs) into stock and withholding for taxes; it does not indicate a discretionary market sale or signal by the insider beyond receiving compensation-related equity.